Evidence map›Paper›PMID 41612982›Full record

ArticleAnnals of gastroenterology

Dietary supplement based on dihydromyricetin in metabolic dysfunction-associated steatotic liver disease: a double-blind, placebo-controlled, randomized clinical trial.

Εlisavet Michailidou, Stavros P Papadakos, Εleni Κoukoulioti, Sofia Paraskevopoulou, Maria Μela, Paraskevi Fytili, Panagiota Ioannidou, Εvangelos Cholongitas, Κonstantinos Τriantafyllou, George V Papatheodoridis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Εlisavet Michailidou1 Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens "Laiko" (Elisavet Michailidou, Stavros P. Papadakos, Sofia Paraskevopoulou, Paraskevi Fytili, Panagiota Ioannidou, Evangelos Cholongitas, George V. Papatheodoridis).
Stavros P Papadakos1 Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens "Laiko" (Elisavet Michailidou, Stavros P. Papadakos, Sofia Paraskevopoulou, Paraskevi Fytili, Panagiota Ioannidou, Evangelos Cholongitas, George V. Papatheodoridis).
Εleni Κoukoulioti2 Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, University General Hospital "Attikon" (Eleni Koukoulioti, Konstantinos Triantafyllou).
Sofia Paraskevopoulou1 Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens "Laiko" (Elisavet Michailidou, Stavros P. Papadakos, Sofia Paraskevopoulou, Paraskevi Fytili, Panagiota Ioannidou, Evangelos Cholongitas, George V. Papatheodoridis).
Maria ΜelaGastroenterology Department, General Hospital of Athens "Evangelismos" (Maria Mela), Athens, Greece.
Paraskevi Fytili1 Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens "Laiko" (Elisavet Michailidou, Stavros P. Papadakos, Sofia Paraskevopoulou, Paraskevi Fytili, Panagiota Ioannidou, Evangelos Cholongitas, George V. Papatheodoridis).
Panagiota Ioannidou1 Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens "Laiko" (Elisavet Michailidou, Stavros P. Papadakos, Sofia Paraskevopoulou, Paraskevi Fytili, Panagiota Ioannidou, Evangelos Cholongitas, George V. Papatheodoridis).
Εvangelos Cholongitas1 Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens "Laiko" (Elisavet Michailidou, Stavros P. Papadakos, Sofia Paraskevopoulou, Paraskevi Fytili, Panagiota Ioannidou, Evangelos Cholongitas, George V. Papatheodoridis).
Κonstantinos Τriantafyllou2 Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, University General Hospital "Attikon" (Eleni Koukoulioti, Konstantinos Triantafyllou).
George V Papatheodoridis1 Department of Gastroenterology, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens "Laiko" (Elisavet Michailidou, Stavros P. Papadakos, Sofia Paraskevopoulou, Paraskevi Fytili, Panagiota Ioannidou, Evangelos Cholongitas, George V. Papatheodoridis).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Despite its increasing prevalence, effective treatment options for metabolic dysfunction-associated steatotic liver disease (MASLD) are limited. We assessed the efficacy of a dietary supplement containing dihydromyricetin (DHM) in MASLD. Methods: Adult MASLD patients were randomized to receive a dietary supplement containing DHM (300 mg/day), vitamins C/E and choline (group A), or identical placebo (group B) for 12 months. Patients were assessed every ≤6 months for clinical and laboratory parameters and liver stiffness measurements (LSM). Results: Fifty-five patients were randomized to group A (n=28) or B (n=27), but 9 patients (group A/B=2/7) were withdrawn early for personal reasons. Median liver enzymes decreased at 6 or 12 months only in group A. Group A compared to B patients achieved higher 12-month rates of combined alanine aminotransferase (ALT)/γ-glutamyl transpeptidase (GGT) normalization (35% vs. 5%, P=0.028). Only in group A, glucose, glycated hemoglobin and total/low density lipoprotein mean levels had declined significantly at 6 and/or 12 months, whereas median liver stiffness measurements (LSM) were lower than baseline at both 6 and 12 months. In multivariate analysis, group A was the only factor associated with ALT/GGT normalization (P=0.038). Generalized estimating equation analysis revealed a significant treatment by time interaction for 12-month combined ALT/GGT normalization only in group A (P=0.021). Conclusions: The 6/12-month use of DHM supplement seems to result in improvements in liver enzymes and LSM, as well as in diabetes and lipid parameters in MASLD patients. Therefore, the use of such a supplement in MASLD needs further evaluation.

Indexed as

elastographyflavonoidsinsulin resistanceMetabolic dysfunction-associated steatotic liver disease

Identifiers

PMID41612982
PMCPMC12850692

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.